Department of Nephrology, First Medical Center of Chinese PLA General Hospital, National Key Laboratory of Kidney Diseases, National Clinical Research Center for Kidney Diseases, Beijing Key Laboratory of Kidney Diseases Research, Beijing, China.
Front Immunol. 2024 Feb 15;15:1326026. doi: 10.3389/fimmu.2024.1326026. eCollection 2024.
For IgA nephropathy (IgAN), tubular atrophy/interstitial fibrosis is the most important prognostic pathological indicator in the mesangial and endocapillary hypercellularity, segmental sclerosis, interstitial fibrosis/tubular atrophy, and presence of crescents (MEST-C) score. The identification of non-invasive biomarkers for tubular atrophy/interstitial fibrosis would aid clinical monitoring of IgAN progression and improve patient prognosis.
The study included 188 patients with primary IgAN in separate confirmation and validation cohorts. The associations of miR-92a-3p, miR-425-5p, and miR-185-5p with renal histopathological lesions and prognosis were explored using Spearman correlation analysis and Kaplan-Meier survival curves. Bioinformatics analysis and dual luciferase experiments were used to identify hub genes for miR-185-5p. The fibrotic phenotypes of tubular epithelial cells were evaluated and in HK-2 cells.
miRNA sequencing and cohort validation revealed that the expression levels of miR-92a-3p, miR-425-5p, and miR-185-5p in urine were significantly increased among patients with IgAN; these levels could predict the extent of tubular atrophy/interstitial fibrosis in such patients. The combination of the three biomarkers resulted in an area under the receiver operating characteristic curve of 0.742. The renal prognosis was significantly worse in the miR-185-5p high expression group than in the low expression group (P=0.003). Renal tissue hybridization, bioinformatics analysis, and dual luciferase experiments confirmed that miR-185-5p affects prognosis in patients with IgAN mainly by influencing expression of the target gene tight junction protein 1 (TJP1) in renal tubular epithelial cells. experiment revealed that an miR-185-5p mimic could reduce TJP1 expression in HK-2 cells, while increasing the levels of α-smooth muscle actin, fibronectin, collagen I, and collagen III; these changes promoted the transformation of renal tubular epithelial cells to a fibrotic phenotype. An miR-185-5p inhibitor can reverse the fibrotic phenotype in renal tubular epithelial cells. In a unilateral ureteral obstruction model, the inhibition of miR-185-5p expression alleviated tubular atrophy/interstitial fibrosis.
Urinary miR-185-5p, a non-invasive biomarker of tubular atrophy/interstitial fibrosis in IgAN, may promote the transformation of renal tubular epithelial cells to a fibrotic phenotype via TJP1.
对于 IgA 肾病(IgAN),肾小管萎缩/间质纤维化是系膜和毛细血管内细胞增多、节段性硬化、间质纤维化/肾小管萎缩和新月体(MEST-C)评分中最重要的预后病理指标。鉴定肾小管萎缩/间质纤维化的非侵入性生物标志物将有助于临床监测 IgAN 的进展并改善患者的预后。
本研究纳入了在独立确认和验证队列中 188 名原发性 IgAN 患者。使用 Spearman 相关分析和 Kaplan-Meier 生存曲线探讨了 miR-92a-3p、miR-425-5p 和 miR-185-5p 与肾脏组织病理学病变和预后的关系。生物信息学分析和双荧光素酶实验用于鉴定 miR-185-5p 的核心基因。在 HK-2 细胞中评估肾小管上皮细胞的纤维化表型。
miRNA 测序和队列验证显示,IgAN 患者尿液中 miR-92a-3p、miR-425-5p 和 miR-185-5p 的表达水平显著升高;这些水平可预测此类患者肾小管萎缩/间质纤维化的程度。三种生物标志物的组合得出的受试者工作特征曲线下面积为 0.742。miR-185-5p 高表达组的肾脏预后明显比低表达组差(P=0.003)。肾组织杂交、生物信息学分析和双荧光素酶实验证实,miR-185-5p 主要通过影响肾小管上皮细胞中紧密连接蛋白 1(TJP1)的靶基因表达影响 IgAN 患者的预后。实验表明,miR-185-5p 模拟物可降低 HK-2 细胞中 TJP1 的表达,同时增加α-平滑肌肌动蛋白、纤连蛋白、胶原 I 和胶原 III 的水平;这些变化促进了肾小管上皮细胞向纤维化表型的转化。miR-185-5p 抑制剂可逆转肾小管上皮细胞的纤维化表型。在单侧输尿管梗阻模型中,抑制 miR-185-5p 的表达可减轻肾小管萎缩/间质纤维化。
IgAN 中肾小管萎缩/间质纤维化的非侵入性生物标志物尿 miR-185-5p 可能通过 TJP1 促进肾小管上皮细胞向纤维化表型转化。